subject area of
- An investigation into the role of prostaglandins in zebrafish oocyte maturation and ovulation Journal Articles
- Appropriate Assessment of the Functional Consequences of Platelet Cyclooxygenase-1 Inhibition by Aspirin in vivo Journal Articles
- Aspirin resistance: does it exist and is it an important clinical problem? Journal Articles
- Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor Journal Articles
- Common polymorphisms of cyclooxygenase-2 and prostaglandin E2 receptor and increased risk for acute coronary syndrome in coronary artery disease Journal Articles
- Cyclooxygenase isoenzymes and patency of ductus arteriosus Conferences
- Differential Effect of a Selective Cyclooxygenase-2 Inhibitor Versus Indomethacin on Renal Blood Flow in Conscious Volume-Depleted Dogs Journal Articles
- Effective, selective and specific inhibition of COX-1 may overcome the “aspirin paradox” Journal Articles
- Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. Journal Articles
- Function of cyclo‐oxygenase‐1 and cyclo‐oxygenase‐2 in the ductus arteriosus from foetal lamb: differential development and change by oxygen and endotoxin Journal Articles
-
Hydrogen sulphide protects against
NSAID ‐enteropathy through modulation of bile and the microbiota Journal Articles - Mechanisms of Aspirin-Intolerant Asthma: Identifying Inflammatory Pathways in the Pathogenesis of Asthma Journal Articles
- Overexpression of the Multidrug Resistance Protein-4 Transporter in Patients Undergoing Coronary Artery Bypass Graft Surgery Journal Articles
- Panax quinquefolium saponin combined with dual antiplatelet drugs inhibits platelet adhesion to injured HUVECs via PI3K/AKT and COX pathways Journal Articles
- Prostaglandin modulation of airway inflammation and hyperresponsiveness in mice sensitized without adjuvant Journal Articles
- Selective Cyclooxygenase-2 Inhibitors as Potential Therapeutic Agents for Inflammatory Diseases Journal Articles
- The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor Journal Articles